Rewind Therapeutics (“Rewind”), a private Belgian biotech company developing innovative first-in-class therapies for myelin-related diseases announces the appointment of Ian J. Reynolds as its Chief Executive Officer (CEO)
- CMS gains exclusive rights to current VAXIMM pipeline and option for future programs for China and other Asian
- VAXIMM to receive potential development and commercial milestone payments plus royalties on sales
- CMS to make an equity investment in VAXIMM
Forendo Pharma, today announces it has received clinical trial authorisation (CTA) from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) to commence a study for its lead program FOR-6219
Financing led by Temasek with new and existing investors including Baillie Gifford, Amgen Ventures, M Ventures, JAZZ Venture Partners, Canepa Advanced Healthcare Funds, and Brooklands Capital Strategies
Proceeds will advance commercial and clinical-stage pipeline in ADHD, multiple sclerosis, and depression
Medisafe, the leading medication management platform released data showing that, on average, hypertensive patients increase their prescription refills by almost 10% after they start using the company's mobile app.
Forendo Pharma today announces that it has been granted a €3 million R&D loan from Business Finland, for the development of a novel drug for endometriosis treatment. Business Finland is the most important public funding agency for research funding in Finland.
"The sale of Prexton Therapeutics to Lundbeck is a very strong validation of our model of founding companies based on spinning-off assets from Merck KGaA, Darmstadt, Germany and managing them very actively as a shareholder. We are very excited to see the program being acquired by Lundbeck, a leading company in the field of neurology, and feel this is a strong confirmation of the investment thesis on which Prexton was founded in 2012 by Francois Conquet and us, namely that modulating mGluR4 is a highly promising therapeutic approach for the sympomatic treatment of Parkinson`s Disease and dyskinesia.", said Jasper Bos, Ph.D., Vice-President and Head of Healthcare of M Ventures, the corporate venture arm of Merck KGaA, Darmstadt, Germany, Board Member of Prexton.
Artios Pharma, a leading DNA Damage Response (DDR) company developing innovative new treatments for cancer, today announces that it has exercised its option to in-license the first nuclease drug development programme under its research collaboration and option agreement with Masaryk University in the Czech Republic. The collaboration was formed in June 2017 to discover and develop novel cancer treatments by targeting DNA nucleases involved in the DDR.